.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical advancements suggest that biological drugs for Sjögren disease could transform the management of salivary dysfunction. Sjögren disease often causes systemic complications, with dry mouth being a hallmark symptom. Researchers are now evaluating how novel biological agents target the underlying pathophysiology of this condition. Consequently, these therapies may offer new hope for patients struggling with persistent hyposalivation.
A systematic review analyzed fourteen randomized clinical trials involving 1,772 patients to assess therapeutic efficacy. The studies focused on various agents, including rituximab, iscalimab, and human interferon (IFN)-α. Specifically, four trials reported that rituximab and iscalimab led to a significant increase in unstimulated whole salivary flow. Furthermore, participants experienced a noticeable improvement in dry mouth sensations. These findings indicate that these agents may restore glandular activity more effectively than traditional palliative care. However, other biologicals like infliximab and tocilizumab did not demonstrate similar benefits in this review. Most patients tolerated the treatments well, with the researchers observing no relevant adverse effects across the included studies.
The potential benefits of these therapies highlight a shifting landscape in autoimmune treatment. Moreover, the integration of biological drugs into clinical practice requires careful patient selection. While rituximab and iscalimab show promise, larger and more standardized trials are still necessary. This will help doctors determine the optimal timing and dosage for these interventions. Currently, these drugs provide a valuable alternative when standard secretagogues fail to provide relief. Additionally, clinicians should remain updated on emerging data regarding long-term safety and efficacy profiles.
Research indicates that rituximab, iscalimab, and human interferon-α are among the most promising biological agents for improving salivary flow and reducing xerostomia symptoms.
The recent systematic review observed no relevant adverse effects in the clinical trials studied, suggesting that these agents are generally well-tolerated by patients.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult with a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Seoane-Romero JM et al. Effectiveness of biological drugs in the treatment of xerostomia and salivary hypofunction in patients with Sjögren disease. J Am Dent Assoc. 2026 Mar 10. doi: undefined. PMID: 41805268.
Pijpe J, Vissink A, Kallenberg CG. The Future of Biologic Agents in the Treatment of Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):519-533. doi: 10.1016/j.rdc.2016.03.010.
Grader-Beck T. Novel Biologic for Sjogren's Clears Penultimate Hurdle. MedPage Today. October 30, 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systematic review highlights the effectiveness of biological drugs like rituximab and iscalimab in treating salivary dysfunction in Sjögren disease....
6 months ago
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Today
A pharmacometric and machine learning study reveals that specific vaginal bacteria alter cervical antiretroviral exposure, highlighting the need for precision HIV PrEP strategies.
Today
A nationwide Swedish cohort study shows oral glucocorticoid exposure over 1-2 years strongly predicts overall organ damage in SLE, while cardiovascular risk reflects cumulative doses across 3 years. These findings reinforce early steroid minimization and cautious long-term maintenance.
Today
A scoping review highlights neural mobilization as a promising adjunct in managing cervicogenic headache. Integrating neurodynamics into multimodal physical therapy improves pain, range of motion, and posture, though standardized protocols and larger clinical trials are still needed.
Today
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Today
